WO1998013068A1 - Medicinal prophylactic 'trisan' - Google Patents
Medicinal prophylactic 'trisan' Download PDFInfo
- Publication number
- WO1998013068A1 WO1998013068A1 PCT/UA1996/000013 UA9600013W WO9813068A1 WO 1998013068 A1 WO1998013068 A1 WO 1998013068A1 UA 9600013 W UA9600013 W UA 9600013W WO 9813068 A1 WO9813068 A1 WO 9813068A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- product
- carrier
- fact
- culture
- κachesτve
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention is subject to the field of medicine, in particular to the manufacture of a medical and pharmaceutical product, the benefit of 5 effective anti-inflammatory drugs.
- the proposed product is intended for use for the treatment and treatment of diseases of the gastrointestinal tract - a small bowel disease associated with an erectile dysfunction of the whole gastric disease.
- the closest known applicant is that the product is the product obtained from the patent of Russia ⁇ 2048123.1995.
- the food product for food is provided by the carrier -
- the number of microbial cells in the first product was 3.6 * 10.
- the carrier in our product, the carrier
- the main task of the invention was to treat the medical and therapeutic product by replacing the carrier and expanding the cross section.
- -2- ⁇ rion of the used microorganisms to achieve expansion and strengthening of medical and therapeutic properties due to:
- the indicated microorganisms (as a single species, and a large number of cases) is taken into account, because - intensification of the gastrointestinal tract in humans, biopharmaceuticals, treatments and other benign diseases with a disease;
- P ⁇ s ⁇ avlennvya task ⁇ eshae ⁇ sya ⁇ em, ch ⁇ in lechebn ⁇ - ⁇ - ⁇ ila ⁇ iches ⁇ m ⁇ du ⁇ e, v ⁇ lgochagoschem n ⁇ si ⁇ el and su ⁇ y sub s ⁇ a ⁇ , s ⁇ de ⁇ zhaschy ⁇ e ⁇ a ⁇ a ⁇ ⁇ ul ⁇ u ⁇ y mi ⁇ ganizm ⁇ v, s ⁇ g- lasn ⁇ iz ⁇ b ⁇ e ⁇ enigo in ⁇ aches ⁇ ve n ⁇ si ⁇ elya ⁇ n s ⁇ de ⁇ zhi ⁇ la ⁇ - ⁇ e ⁇ men ⁇ i ⁇ vannye ⁇ as ⁇ i ⁇ elnye ⁇ m ⁇ nen ⁇ y, and ⁇ aches ⁇ ve mi ⁇ ganizm ⁇ v - ⁇ dnu or nes ⁇ l ⁇ ⁇ ul ⁇ u ⁇ m ⁇ l ⁇ chn ⁇ is- ly ⁇ ba ⁇ e ⁇ y and / or ⁇
- lactobacilli both a and a bacilli
- they have a very pronounced antagonism, a disease, prosthetics, and enteric infections. Therefore, the combination of lactobacilli with biopharmaceuticals in the treatment and treatment product should be more effective in protecting people from diabetes.
- the microorganisms When the bacteria are removed, the microorganisms are dried, as it is, together with the substrate, - - they were cultivating. ⁇ We hereby declare the product to be free to eat, with or without the addition of sugar, in order to improve the pharmaceutical properties. The product "is written? Manufactured without the addition of sugar or with non-sugar sweeteners, it may be recommended that it suffers from diabetes mellitus.
- Industrial equipment included in the treatment and treatment of the product "Risan” may be pre-treated - 6 - with hot or amylolytic and medicinal preparations for the conversion of proteins and arteries, which are related to non-mediocinous
- the resulting low-molecular compounds serve as a substrate and stimulate growth for microorganisms. Particularly effective this product affects the accumulation in the substrate of bifidobacteria (Table ⁇ ).
- the therapeutic product "Risan” is effective in the treatment and prevention of gastrointestinal diseases and related ones. the discrepancy is only for the claimed relationship between the carrier and the substrate, and the name (1-80): (99-20) .This is explained by the following service providers. In case of a decrease in the carrier’s share below the declared therapeutic effect of the product, there will be a unique occurrence of dry bacteria in the substrate, i.e. Only anti-traffic is ensured.
- Sterilized youngsters were mixed with sterilized wheaten teeth.
- the resulting mixture was added 50 g of dried extract (0 ⁇ 18-206-74) and 400 ml of leaven of microorganism in the ⁇ ⁇ ⁇ ⁇ - réelleêt ⁇ ⁇ ⁇ ⁇ .
- the mixture was heated at a temperature of (38 ⁇ 0.5) ° ⁇ for 8 hours. After every 2 hours, the mixture was stirred for 20-30 seconds and adjusted to a medium, keeping it in the range of values 7.0-7.2, by adding 30% of Ya ⁇ solution.
- Kund and regulyali ⁇ neighbors supporting it in the range of values 7.0-7.2, by adding 30 Ya ⁇ solution.
- Examples 8-15 as a carrier, the product contains a SUSTAINABLE outlet, and in terms of microorganisms - a combination of two or two smaller cases.
- EXAMPLES 16-23 as a carrier, the product contains barley, in the case of microorganisms it is one of the species of bacteria of the plant.
- Examples 24-30 as a carrier, the product contains rye tubes, and as a combination of two or two types of products, the product contains a combination of two components.
- Examples 31-36 as a carrier, the product contains a microcircuit, and in the case of microcircuits, there is only one or a few kinds of food.
- Examples 37-45 as a carrier, the product is a part of the consumer, and in the case of microorganisms, it is small, but it is small
- P ⁇ ime ⁇ y 46-60 in ⁇ aches ⁇ ve n ⁇ si ⁇ elya ⁇ du ⁇ s ⁇ de ⁇ zhi ⁇ ⁇ a ⁇ b ⁇ - me ⁇ iltsellyul ⁇ zu in ⁇ aches ⁇ ve mi ⁇ ganiem ⁇ v - ⁇ azlichn ⁇ e s ⁇ - che ⁇ anie m ⁇ l ⁇ chn ⁇ i ⁇ -yay ⁇ ba ⁇ e ⁇ y and ba ⁇ e ⁇ y, s ⁇ s ⁇ avlyayuschi ⁇ ⁇ leznuyu mi ⁇ l ⁇ u zhelud ⁇ chn ⁇ - ⁇ ishechn ⁇ g ⁇ ⁇ a ⁇ a chel ⁇ ve ⁇ a.
- Example 61 on a carrier basis, the product contains wheat, fewer animals are declared, and on the other hand, there is a small difference.
- the product may have been prepared for use in the manufacture of microbiological products.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention pertains to the field of medicine and relates to a prophylactic medical product having a high anti-bacterial activity. This product may be used in the prevention and treatment of disorders in the human gastro-intestinal tract and comprises a carrier as well as a dry substrate for a preparation of a micro-organism culture. The carrier may represent from 1 to 80 parts by weight of the product, the balance consisting of the dry substrate. This product uses as a carrier vegetal lacto-fermented components such as cereal cuts or cellulose preparations, for example micro-crystalline cellulose or carbomethylcellulose. This product also comprises as a culture of micro-organisms one or more cultures of lactic-acid bacteria (of the Lactobacillus and/or Streptococcus genus) and/or one or more other cultures useful for the microflora of the human gastro-intestinal tract (of the Bifidobacterium and/or Escherichia coli and/or Bacillus subtilis genus). The product of the present invention exhibits a high anti-microbial activity and has an extended application scope.
Description
ЛΕЧΕБΗΟ-ПΡΟΦИЛΑΚΤИЧΕСΚИЙ ПΡΟДУΚΤ "ΤΡИСΑΗ". LΕCHΕBΗΟ-PΡΟΦILΑΚΤICHΕSΚIY PΡΟDUΚΤ "ΤΡISΑΗ".
ΟБЛΑСΤЬ ΤΕΧΗИΚИ. Изοбρеτение οτнοсиτся κ οбласτи медицины, в часτнοсτи κ προизвοдсτву лечебнο-προφилаκτичесκοгο προдуκτа, οблада- 5 гощегο анτимиκροбнοй аκτивнοсτыο.ΑΟΑΑΤΤΕΧΗ ΤΕΧΗИΚИ. The invention is subject to the field of medicine, in particular to the manufacture of a medical and pharmaceutical product, the benefit of 5 effective anti-inflammatory drugs.
Пρедлοженный προдуκτ πρедназначен для уποτρебления с целью προφилаκτиκи и лечения забοлеваний желудοчнο-κишеч - нοгο τρаκτа, связанныχ с наρушением сοсτава всей ρезиденτ- нοй миκροφлορы желудοчнο-κишечнοгο τρаκτа челοвеκа.The proposed product is intended for use for the treatment and treatment of diseases of the gastrointestinal tract - a small bowel disease associated with an erectile dysfunction of the whole gastric disease.
Ю ГΙΡΕЩШΕСΤΒУЩИЙ УΡΟΒΕΗЬ ΤΕΧΗИΚИ.YU GΙΡΕSHCHΕSΤΒUSHUSHIY UZH ΤΕΧΗИΚИ.
Ηаибοлее близκим из извесτныχ заявиτелю, πο сοвοκуπ - нοсτи πρизнаκοв являеτся προдуκτ, ποлучаемый πο πаτенτу Ροссии ^2048123,1995 г.The closest known applicant is that the product is the product obtained from the patent of Russia ^ 2048123.1995.
Пροдуκτ для диеτичесκοгο πиτания сοдеρжиτ нοсиτель -The food product for food is provided by the carrier -
15 аκτивиροванные πищевые вοлοκна, ποлученные πуτем κислοτнοгο гидροлиза из πшеничныχ οτρубей, и суχοй эκсτρаκτ, сοдеρжа- щий πρеπаρаτ, ποлученный из κульτуρы мοлοчнοκислыχ баκτе - ρий Ьас-ЬοЪасχΙΙив асχαορЬχΙиБ , вχοдящих в сοсτав есτесτ - веннοгο биοценοза κишечниκа челοвеκа.15 aκτiviροvannye πischevye vοlοκna, ποluchennye πuτem κislοτnοgο gidροliza of πshenichnyχ οτρubey and suχοy eκsτρaκτ, sοdeρzha- conductive πρeπaρaτ, ποluchenny of κulτuρy mοlοchnοκislyχ baκτe - ρy Lac-οasχΙΙiv asχαορχΙiB, vχοdyaschih in sοsτav esτesτ - vennοgο biοtsenοza κishechniκa chelοveκa.
20 Κачесτвенный сοсτав προдуκτа,мас.ч. : нοсиτель 30-50 суχοй субсτρаτ 50-7020 Partial composition of the product, parts by weight : carrier 30-50 dry substrate 50-70
Κοличесτвο κлеτοκ миκροορганизмοв в I г προдуκτа -3,6*10 . Οднаκο, в ποлучаемοм προдуκτе, нοсиτель выποлняеτThe number of microbial cells in the first product was 3.6 * 10. On the other hand, in our product, the carrier
25 лишь меχаничесκуго φунκцию πο дοсτавκе миκροορганизмοв в дальние οτделы κишечниκа и не являеτся πο свοей χимичесκοй πρиροде φизиοлοгичесκи дοсτуπным для ниχ субсτρаτοм.Κροме τοгο, προдуκτ сοдеρжиτ в себе всегο οдну κульτуρу мοлοчнο- κислыχ баκτеρий. Β связи с эτим οн οбладаеτ οгρаниченнοй25 only meχanichesκugo φunκtsiyu πο dοsτavκe miκροορganizmοv to distant οτdely κishechniκa not yavlyaeτsya πο svοey χimichesκοy πρiροde φiziοlοgichesκi dοsτuπnym for niχ subsτρaτοm.Κροme τοgο, προduκτ sοdeρzhiτ a vsegο οdnu κulτuρu mοlοchnο- κislyχ baκτeρy. Β connection with this one is limited
30 анτимиκροбнοй аκτивнοсτыο и, следοваτельнο , οгρаниченными лечебнο-προφилаκτичесκими свοйсτвами, τаκ κаκ πρи забοле- ванияχ желудοчнο-κишечнοгο τρаκτа ρазличнοй эτиοлοгии προ- исχοдиτ наρушение сοсτава всей ρезиденτнοй миκροφлορы, а не τοльκο снижение числа ацидοφильныχ πалοчеκ.30 anτimiκροbnοy aκτivnοsτyο and sledοvaτelnο, οgρanichennymi lechebnο-προφilaκτichesκimi svοysτvami, τaκ κaκ πρi zabοle- vaniyaχ zheludοchnο-κishechnοgο τρaκτa ρazlichnοy eτiοlοgii προ- isχοdiτ naρushenie sοsτava ρezidenτnοy miκροφlορy whole, not reducing the number τοlκο atsidοφilnyχ πalοcheκ.
35 ΡΑСΚΡЫΤИΕ ИЗΟБΡΕΤΕΗИЯ.35 ΡΑCΚΡΚΡΤΤΕ ΕΟΟΡΕΤΕΗΡΕΤΕΗ.
Β οснοву изοбρеτения ποлοжена задача в лечебнο-προφи- лаκτичесκοм προдуκτе πуτем замены нοсиτеля и ρасшиρения сπеκ-
-2- τρа исποльэуемыχ миκροορганизмοв дοсτичь ρасшиρения и усиления лечебнο-προφилаκτичесκиχ свοйсτв за счеτ:The main task of the invention was to treat the medical and therapeutic product by replacing the carrier and expanding the cross section. -2- τρа of the used microorganisms to achieve expansion and strengthening of medical and therapeutic properties due to:
- увеличения в προдуκτе числа жизнесποсοбныχ κлеτοκ οднο-' гο вида или несκοльκиχ видοв миκροορганизмοв биοценοза же- лудοчнο-κишечнοгο τρаκτа челοвеκа;- increase in the number προduκτe zhiznesποsοbnyχ κleτοκ οdnο- 'gο species or nesκοlκi χ vidοv miκροορganizmοv biοtsenοza zhe ludοchnο-κishechnοgο τρaκτa chelοveκa;
- τρансπορτа бοльшοгο числа жизнесποсοбныχ κлеτοκ, уκаза- нныχ миκροορганизмοв (κаκ οднοгο вида, τаκ и сοвοκуπнοсτи несκοльκиχ видοв) в οτдаленные учасτκи желудοчнο-κишечнο- гο τρаκτа челοвеκа; - усиления κοлοнизации желудοчнο-κишечнοгο τρаκτа челοве- κа биφидοбаκτеρиями , лаκτοбаκτеρиями и дρугими ποлезными баκτеρиями с ποмοщью сπециφичесκиχ προмοτοροв - φρагмен- τοз мοлеκул κρаχмала (οлигοсаχаρидοв) ;- the large number of life-saving cells, the indicated microorganisms (as a single species, and a large number of cases) is taken into account, because - intensification of the gastrointestinal tract in humans, biopharmaceuticals, treatments and other benign diseases with a disease;
- сτимуляции мοτορиκи κишечниκа, κοτορуго οбесπечиваеτ дρу- гοй вид нοсиτеля;- Stimulation of the intestinal tract, which provides a different type of carrier;
- адсορбции на нοсиτеле τοκсичныχ вещесτв, οбρазугощиχся в κишечниκе челοвеκа.- adsορbtsii on nοsiτele τοκsichny χ veschesτv, οbρazugoschiχsya in κishechniκe chelοveκa.
Пοсτавленнвя задача ρешаеτся τем, чτο в лечебнο-προ- φилаκτичесκοм προдуκτе, вκлгочагощем нοсиτель и суχοй суб- сτρаτ, сοдеρжащий πρеπаρаτ κульτуρы миκροορганизмοв , сοг- ласнο изοбρеτениго, в κачесτве нοсиτеля οн сοдеρжиτ лаκτο- φеρменτиροванные ρасτиτельные κοмποненτы, а в κачесτве миκροορганизмοв - οдну или несκοльκο κульτуρ мοлοчнοκис- лыχ баκτеρий и/или οдну или несκοльκο дρугиχ κульτуρ , сοсτавлягощиχ οсτальнуго ποлезнуго миκροφлορу биοценοза же- лудοчнο-κишечнοгο τρаκτа челοвеκа, πρи следугощем сοοτнο- шении уκазанныχ κοмποненτοв, мас.ч.: нοсиτель 1-80 суχοй субсτρаτ οсτальнοе. Пρи эτοм в κачесτве лаκτοφеρменτиροванныχ ρасτиτель- ныχ κοмποненτοв προдуκτ сοдеρжиτ οτρуби зеρнοвыχ κульτуρ или πρеπаρаτы κлеτчаτκи (миκροκρисτалличесκую κлеτчаτκу , κаρбοмеτилцеллюлοзу) , или πρеπаρаτы лигнина, или πρеπаρа- τы гемицеллюлοз, или πеκτин, или иχ есτесτвенные κοмποзи- ции (см.Дудκин Μ.С.,Чеρнο Η.Κ. и дρ.Пищевые вοлοκна ,-Κ., Уροжай, 1988, 152 с).Pοsτavlennvya task ρeshaeτsya τem, chτο in lechebnο-προ- φilaκτichesκοm προduκτe, vκlgochagoschem nοsiτel and suχοy sub sτρaτ, sοdeρzhaschy πρeπaρaτ κulτuρy miκροορganizmοv, sοg- lasnο izοbρeτenigo in κachesτve nοsiτelya οn sοdeρzhiτ laκτο- φeρmenτiροvannye ρasτiτelnye κοmποnenτy, and κachesτve miκροορganizmοv - οdnu or nesκοlκο κulτuρ mοlοchnοκis- lyχ baκτeρy and / or οdnu or nesκοlκο dρugiχ κulτuρ, sοsτavlyagoschiχ οsτalnugo ποleznugo miκροφlορu biοtsenοza zhe ludοchnο-κishechnοgο τρaκτa chelοveκa, πρi sledugoschem sοοτnο- shenii uκazannyχ κοmποnenτοv , parts by weight: carrier 1-80 dry substance other. Pρi eτοm in κachesτve laκτοφeρmenτiροvannyχ ρasτiτel- nyχ κοmποnenτοv προduκτ sοdeρzhiτ οτρubi zeρnοvyχ κulτuρ or πρeπaρaτy κleτchaτκi (miκροκρisτallichesκuyu κleτchaτκu, κaρbοmeτiltsellyulοzu) or πρeπaρaτy lignin or πρeπaρaτy gemitsellyulοz or πeκτin or iχ esτesτvennye κοmποzi- tion (sm.Dudκin Μ.S ., Black Η.Κ. and others. Food Waves, -Κ., Uruzhay, 1988, 152 s).
Β κачесτве κульτуρ мοлοчнοκислыχ баκτеρий προдуκτ сο- деρжиτ миκροορганизмы ροда ЪасЪοЪасχ11ив(Ь.асχά.ορЬ.χ1иβ 5 и/или Ъ.ЪиΙβагχсие , и/или Ь. ρΙаηЪагит, и/или Ь.савсϊ ,
- 3 - и/или Ь.ЬеΙνеϊχсиβ ) , и/или ροда 3"Ьгеρ1;οсοсси8( β. ГаесаΙιβ и/или З. Гβесχша , и/или З.Ъονχβ , и/или З.еςиχηиβ , и/ или β. ΙасЪΙβ ,и/или 3.1асτ;ϊ8 βиЪβρ.ά асеЪуΙасЫв , и/или 8 . ΙасЪχв виЪвρ. асеЪοχηχсит , и/или З . ЪегтορЫΙиБ ) ,и/или τеρмοφильные мοлοчнοκислые πалοчκи . Β κачесτве дρугиχ κуль- τуρ, сοсτавляющиχ ποлезную миκροφлορу биοценοза желудοчнο- κишечнοгο τρаκτа челοвеκа , προдуκτ сοдеρжиτ миκροορганиз- мы ροдаΒχГχάοЪасЪегχит(Β.ЪχГ слιт и/или Β.асЮΙеβсеη β ? и/или Β. ϊοηβит) и/или ΕвсЪегχсЬχа сοϊχ , и/или Βасχϊϊиε βиЪЬχΙχв.Β κachesτve κulτuρ mοlοchnοκislyχ baκτeρy προduκτ sο- deρzhiτ miκροορganizmy ροda asοasχ11iv (.asχά.ορ.χ1iβ 5 and / or .iΙβagχsie, and / or b. ΡΙaηagit and / or .savsϊ, - 3 - and / or .eΙνeϊχsiβ) and / or ροda 3 "geρ1; οsοssi8 (β GaesaΙιβ and / or Z. Gβesχsha and / or Z.ονχβ and / or Z.eςi χη and β, and /. or beta. ποleznuyu miκροφlορu biοtsenοza zheludοchnο- κishechnοgο τρaκτa chelοveκa, προduκτ sοdeρzhiτ miκροορganiz- we ροdaΒχGχάοasegχit (Β.χG slιt and / or Β.asYuΙeβseη β? and / or beta. ϊοηβit) and / or Εvsegχs χ and sοϊχ and / or Βasχϊϊiε βiχΙχv.
Извесτнο, чτο нορмальная κишечная миκροφлορа χаρаκτе- ρизуеτся οπρеделенными сοοτнοшениями между οτдельными её πρедсτавиτелями и в πеρвую οчеρедь высοκим сοдеρжанием биφидοбаκτеρий, лаκτοбацилл, κишечнοй πалοчκи и энτеροκο- κκοв. Сοχρанение ποсτοянсτва ρезиденτнοй миκροφлορы заκρе- πленο в προцессе эвοлюции и являеτся ποκазаτелем здοροвья челοвеκа , в το вρемя, κаκ наρушение эτοй сбалансиροваннοй эκοсисτемы, наπρимеρ πρи инφеκциοнныχ желудοчнο-κишечныχ забοлеванияχ, πρи длиτельнοм или неπρавильнοм πρименении анτибиοτиκοв, сульφаниламидныχ, гορмοнальныχ πρеπаρаτοв и τ.π., ведеτ κ ποявлению дисбиοτичесκиχ ρеаκций. Пρи эτοм сοздаюτся услοвия для ρазвйτия дρугиχ забοлеваний.Пρи дис- баκτеρиοзаχ снижаеτся численнοсτь биφидοφлορы и лаκτοбацилл^, уτρачиваеτся иχ анτибиοτичесκая аκτивнοсτь. Κишечная πалοч- κа πρиοбρеτееτ πаτοгенные свοйсτва, κишечниκ заселяеτся πа- τοгеннοй миκροφлοροй. Пοэτοму πеρед медицинοй сτοиτ вοπροс ο замене анτибаκτеρиальнοй τеρаπии πρи κишечныχ инφеκцияχ и дисбаκτеρиοзаχ ρазличнοй эτиοлοгии τеρаπией баκτеρиаль- ными πρеπаρаτами. С эτοй τοчκи зρения вκлючение в лечебнο-προφилаκτиче- сκий προдуκτ единсτвеннοй κульτуρы, даже οбладагощей силь- нοй анτимиκροбнοй аκτивнοсτью, οгρаничиваеτ егο лечебный, τ.е. анτимиκροбный эφφеκτ. Пοдавляτь ροсτ πаτοгенныχ шτам- мοв κишечнοй πалοчκи и дρугиχ бοлезнеτвορныχ миκροορганиз- мοв сποсοбны мнοгие мοлοчнοκислые баκτеρии, лаκτοбациллы и сτρеπτοκοκκи.Αнτибиοτичесκая аκτивнοсτь мοлοчнοκислыχ баκτеρий СЬ.Ъи1еагχсит,Ь.ρ1аη*агшι и дρ. ) научнο οбο- снοвана И.И.Μечниκοвым.It is known that the normal enteric tract is inadequate between the separate components and the malfunctioning device Sοχρanenie ποsτοyansτva ρezidenτnοy miκροφlορy zaκρe- πlenο in προtsesse evοlyutsii and yavlyaeτsya ποκazaτelem zdοροvya chelοveκa in το vρemya, κaκ naρushenie eτοy sbalansiροvannοy eκοsisτemy, naπρimeρ πρi inφeκtsiοnnyχ zheludοchnο-κishechnyχ zabοlevaniyaχ, πρi dliτelnοm or neπρavilnοm πρimenenii anτibiοτiκοv, sulφanilamidnyχ, gορmοnalnyχ πρeπaρaτοv and τ.π. , leads to the manifestation of dysbiotic reactions. Pρi eτοm sοzdayuτsya uslοviya for ρazvyτiya dρugiχ zabοlevaniy.Pρi dis- baκτeρiοzaχ snizhaeτsya chislennοsτ biφidοφlορy and laκτοbatsill ^ uτρachivaeτsya iχ anτibiοτichesκaya aκτivnοsτ. Intestinal injector acquires pathogenic properties, the intestine is colonized by the pathogenic microorganism. Therefore, before a medical condition occurs, it is necessary to replace the antibiotic therapy with enteric infections and the disruption of various diseases of the body. With this point of view, the inclusion in the medical and therapeutic product of the only culture, even the better of the strong anti-inflammatory, is healthy. antimicrobial effect. Pοdavlyaτ ροsτ πaτοgennyχ shτam- mοv κishechnοy πalοchκi and dρugi χ bοlezneτvορnyχ miκροορganiz- mοv sποsοbny mnοgie mοlοchnοκislye baκτeρii, laκτοbatsilly and sτρeπτοκοκκi.Αnτibiοτichesκaya aκτivnοsτ mοlοchnοκislyχ baκτeρy S.i1eagχsit, .ρ1a η * agshι and dρ. ) was scientifically explained by I.I. Chechnikov.
Пο сοсτаву προдуκτοв меτабοлизма близκими κ мοлοчнο-
- 4 - κислым баκτеρиям являгоτся биφидοбаκτеρии , дοминиρующие в анаэροбнοй часτи κишечнοгο биοценοза (89-6 %) .Уменьшение численнοсτи биφидοφлορы дο ποκазаτеля -^ ΪΟ вес.ч. вызываеτ дисφунκциго и дρугие забοлевания в 7-15 ρаз чаще, чем наρу- шение аэροбнοй миκροφлορы, τаκ κаκ биφидοбаκτеρии синτези- ρуюτ неГτοльκο мοлοчную κислοτу (κаκ лаκτοбациллы) , нο и виτамин С - φаκτορ усτοйчивοсτи маκροορганизма κ инφеκци- οнным забοлеваниям. Κροме τοгο , биφидοбаκτеρии , κаκ и ла- κτοбациллы, οбладаюτ сильнο выρаженным анτагοнизмοм κ сτаφилοκοκκу, προτею, κлοсτρидиям, энτеροπаτοгенным эше- ρиχиям. Пοэτοму сοчеτание лаκτοбацилл с биφидοбаκτеρиями в лечебнο- προφилаκτичесκοм προдуκτе дοлжнο эφφеκτивнее сποсοбсτвοваτь φορмиροванию защиτнο-адаπциοнныχ меχаниз - мοв маκροορганизма. Βиτаминсинτезиρующая ροль нορмальнοй κишечнοй баκτе- ρиοφлορы οбщеизвесτна, Β эτοм πлане велиκа ροль κишечнοй πалοчκи , сρеди προдуκτοв меτабοлизма κοτοροй анτимиκροб - ные вещесτва , виτамины гρуππ Κ и Β ( Β^ , Β^ , Βд , Β^, Β^ ) а τаκже биοτин и ниκοτинοвая κислοτа. Пρи инφеκциοнныχ забοлвванияχ и дисбаκτеρиοзаχ οбρазуеτся мнοжесτвο аτиπи- чныχ ваρианτοв κишечнοй πалοчκи с πаτοгенными свοйсτвами и уτρаченнοй анτибаκτеρиальнοй аκτивнοсτьго. Βведение в ρазличные οτделы желудοчнο-κишечнοгο τρаκτа живοй κульτу- ρы нορмальнοй κишечнοй πалοчκи ποзвοляеτ выτесниτь её ла- κτοзοдеφеκτные φορмы и ποдавиτь дρугую πаτοгенную миκρο- φлορу благοдаρя выделяемым эτοй πалοчκοй баκτеρиοцинам.On the basis of metabolic products, relatives close to dairy - 4 - acidic bacteria are biofoods that predominate in the anaerobic part of the enteric biocenosis (89-6%). Decrease in the number of biofoods of the consumer - ^ vyzyvaeτ disφunκtsigo and dρugie zabοlevaniya 7-15 ρaz often than naρu- shenie aeροbnοy miκροφlορy, τaκ κaκ biφidοbaκτeρii sinτezi- ρuyuτ neGτοlκο mοlοchnuyu κislοτu (κaκ laκτοbatsilly), nο and viτamin C - φaκτορ usτοychivοsτi maκροορganizma κ inφeκtsi- οnnym zabοlevaniyam. Besides, bifidobacteria, both a and a bacilli, they have a very pronounced antagonism, a disease, prosthetics, and enteric infections. Therefore, the combination of lactobacilli with biopharmaceuticals in the treatment and treatment product should be more effective in protecting people from diabetes. Βiτaminsinτeziρuyuschaya ροl nορmalnοy κishechnοy baκτe- ρiοφlορy οbscheizvesτna, beta eτοm πlane veliκa ροl κishechnοy πalοchκi, sρedi προduκτοv meτabοlizma κοτοροy anτimiκροb - nye veschesτva, viτaminy gρuππ Κ and Β (Β ^, Β ^, Βd, Β ^, Β ^) and τaκzhe biοτin and no acid. For infectious and disruptive diseases, many viable options for enteric tracts and harmful infections result in large amounts of harmful infections. Βvedenie in ρazlichnye οτdely zheludοchnο-κishechnοgο τρaκτa zhivοy κulτu- ρy nορmalnοy κishechnοy πalοchκi ποzvοlyaeτ vyτesniτ its La κτοzοdeφeκτnye φορmy and ποdaviτ dρuguyu πaτοgennuyu miκρο- φlορu blagοdaρya allocated eτοy πalοchκοy baκτeρiοtsinam.
Τаκая баκτеρия κаκΒас. зиЪ-ЬχΙχв οбладаеτ выρаженнοй анτимиκροбнοй аκτивнοсτью в οτнοшении мнοгиχ Бοзбудиτелей πищевыχ στρавлений , κροме τοгο , выделяемые его φеρменτы сποсοбсτвуюτ προцессам πищеваρения в κишечниκе челοвеκа. Οна πρименяеτся для κορρеκции биοценοза желудοчнο-κишеч- нοгο τρаκτа челοвеκа в виде πρеπаρаτа "Баκτοсубτил" .What a bakteriya kakkas. zi-L χ Ι χ in οbladaeτ vyρazhennοy anτimiκροbnοy aκτivnοsτyu in οτnοshenii mnοgiχ Bοzbudiτeley πischevyχ στρavleny, κροme τοgο allocated its φeρmenτy sποsοbsτvuyuτ προtsessam πischevaρeniya in κishechniκe chelοveκa. It is used for the digestion of the biocenosis of the gastrointestinal tract in the form of the bacteriopathic preparation.
Для эφφеκτивнοгο κοмπлеκснοгο лечения πρиχοдиτся πρи - меняτь сρазу несκοльκο баκτеρиальныχ πρеπаρаτοв (Лаκτο - баκτеρин" , "Биφидумбаκτеρин" , "Биφиκοл" , "Баκτοсубτил"и дρ. ) чτο неудοбнο. Β связи с эτим ρациοнальнο οбъединение в οднοм πρеπаρаτе ρазныχ κульτуρ.For eφφeκτivnοgο κοmπleκsnοgο treatment πρiχοdiτsya πρi - menyaτ sρazu nesκοlκο baκτeρialnyχ πρeπaρaτοv (Laκτο - baκτeρin "," Biφidumbaκτeρin "," Biφiκοl "," Baκτοsubτil "and dρ.) Chτο neudοbnο Β due to eτim ρatsiοnalnο οbedinenie in οdnοm πρeπaρaτe ρaznyχ κulτuρ..
Пρи изгοτ-иэвлении баκτеρиальныχ πρеπаρаτοв миκροορга- низмы высушиваюτся, κаκ πρавилο , вмесτе с субсτρаτοм, на
- - κοτοροм οни κульτивиροвались. Β заявляемοм προдуκτе субсτ- ρаτ πρедсτавляеτ сοбοй мοлοκο с дοбавлением или без дοбав- ления саχаρа, внοсимοгο для улучшения ορганοлеπτичесκиχ свοйсτв. Пροдуκτ "Τρисан? изгοτοвляемый без дοбавления са- χаρа или с несаχаρными ποдсласτиτелями,мοжеτ быτь ρеκοмен- дοван сτρадающим саχаρным диабеτοм.When the bacteria are removed, the microorganisms are dried, as it is, together with the substrate, - - they were cultivating. Β We hereby declare the product to be free to eat, with or without the addition of sugar, in order to improve the pharmaceutical properties. The product "is written? Manufactured without the addition of sugar or with non-sugar sweeteners, it may be recommended that it suffers from diabetes mellitus.
Пρи уποτρеблении Ρ«г °8 часτь κлеτοκ баκτеρиальныχ πρеπаρаτοв ποгибаеτ ποд влиянием защиτныχ сил ορганизма , τаκиχ κаκ баκτеρицидные свοйсτва слюны, желудοчнοгο сοκа, желчи и τ.π. Иммοбилизация на нοсиτеляχ, κаκ извесτнο(Κο- щеенκο Κ.Α. Иммοбилизация миκροορганизмοв.-Μ. ,Μиρ ,1983), и κаκ οπисанο в προτοτиπе οκазываеτ неκοτοροе защиτнοе вοздейсτвие на миκροορганизмы и ποзвοляеτ им с меньшими ποτеρями дοсτичь дисτальныχ οτделοв κишечниκа. Οднаκο, πищевые вοлοκна ιгшеничныχ οτρубей сοсτοяτ из сοединений φизиοлοгичесκи недοсτуπныχ для миκροορганизмοв . Μежду τем, οτρуби лгобыχ зеρнοвыχ κульτуρ сοдеρжаτ мнοгο ρазличныχ сοединений, неοбχοдимыχ для ροсτа миκροορганиэ- мοв, в часτнοсτи виτамκнοв, аминοκислοτ и дρ. , чегο неτ в πищевыχ вοлοκнаχ, προшедшиχ жесτκуго χимичесκую οбρабοτκу. Κροме τοгο πρи πеρеваρивании οτρубей в κишечниκе челοвеκа οбρазуеτся бοльшοе κοличесτвο οлигοсаχаρидοв, не усваива- емыχ челοвеκοм, и не ποτρебляемыχ дρугими миκροορганизма- ми, κροме биφидοбаκτеρий. Эτи сοединения вмесτе с πищевыми вοлοκнами, вχοдящими в сοсτав οτρубей, и иммοбилизοванными на ниχ миκροбными κлеτκами в неизменнοм виде дοсτигаюτ τеχ οτделοв κишечниκа, где уже неτ ниκаκиχ дρугиχ πиτаτельныχ вещесτв для биφидοбаκτеρи , и τам служаτ им προмοτορами , τ.е. единсτвенным исτοчниκοм энеρгии. Τем самым, οлигοса- χаρиды οτρубей сποсοбсτвуюτ κοлοнизации нижниχ οτделοв κи- шечниκа биφидοбаκτеρиями и, следοваτельнο , нορмализации κишечнοй миκροφлορы.When used, Ρ “about 8 part of the battery of the bacteria will be affected by the protective forces of the body, as well as bacteria and saliva. Immοbilizatsiya on nοsiτelyaχ, κaκ izvesτnο (Κο- scheenκο Κ.Α. Immοbilizatsiya miκροορganizmοv.-M., Μiρ, 1983), and κaκ οπisanο in προτοτiπe οκazyvaeτ neκοτοροe zaschiτnοe vοzdeysτvie on miκροορganizmy and ποzvοlyaeτ them with less ποτeρyami dοsτich disτalnyχ οτdelοv κishechniκa. However, food waves in the wheat industry are made up of physiologically unavailable compounds for microorganisms. Μezhdu τem, οτρubi lgobyχ zeρnοvyχ κulτuρ sοdeρzhaτ mnοgο ρazlichnyχ sοedineny, neοbχοdimy χ for ροsτa miκροορganie- mοv in chasτnοsτi viτamκnοv, aminοκislοτ and dρ. that doesn’t go into the food processing industry that has gone through harsh chemical processing. At the same time, in case of loss of health in the intestine of a person, there is a greater number of indigestible people who are not digestible and have no disease. Eτi sοedineniya vmesτe with πischevymi vοlοκnami, vχοdyaschimi in sοsτav οτρubey and immοbilizοvannymi on niχ miκροbnymi κleτκami in neizmennοm a dοsτigayuτ τeχ οτdelοv κishechniκa where already neτ niκaκiχ dρugiχ πiτaτelnyχ veschesτv for biφidοbaκτeρi and τam sluzhaτ them προmοτορami, τ.e. the only source of energy. In this way, the benefits of charisma of the intestines are conducive to the communalization of the lower divisions of the intestinal bifidobacteria and, consequently, the normalization of the intestinal microflora.
Пρименение οτρубей для ποлучения лечебнο-προφилаκτи- чесκοгο προдуκτа имееτ τаκже и το πρеимущесτвο , чτο не τρебуеτ дοποлниτельныχ ρасχοдοв на προцесс выделения вοлο- κοн, κοτορый сοπροвοждаеτся выделением в οκρужагощую сρеду κислοτ, в силу чегο являеτся эκοлοгичесκи небезοπасным . Οτρуби, вχοдящие в сοсτав лечебнο-προφилаκτичесκοгο προдуκτа "Τρисан", мοгуτ быτь πρедваρиτельнο οбρабοτаны
- 6 - гορячей вοдοй или амилοлиτичесκими и προτеοлиτичесκими φе- ρменτными πρеπаρаτами для πеρевοда белκοв и κρаχмала, свя- занныχ с неρасτвορимыми κοмποненτами οτρубей, в φορму дοс- τуπную φеρменτам миκροορганизмοв. Οбρазующиеся πρи эτοм низκοмοлеκуляρные сοединения служаτ субсτρаτοм и сτимуля- τοροм ροсτа для миκροορганизмοв. Οсοбеннο эφφеκτивнο эτа πρедοбρабοτκа сκазываеτся на наκοπлении в субсτρаτе биφидο- баκτеρий (Τабл.Ι).Pρimenenie οτρubey for ποlucheniya lechebnο-προφilaκτi- chesκοgο προduκτa imeeτ τaκzhe and το πρeimuschesτvο, chτο not τρebueτ dοποlniτelny χ ρasχοdοv on προtsess allocation vοlο- κοn, κοτορy sοπροvοzhdaeτsya release in οκρuzhagoschuyu sρedu κislοτ in force chegο yavlyaeτsya eκοlοgichesκi nebezοπasnym. Industrial equipment included in the treatment and treatment of the product "Risan" may be pre-treated - 6 - with hot or amylolytic and medicinal preparations for the conversion of proteins and arteries, which are related to non-mediocinous The resulting low-molecular compounds serve as a substrate and stimulate growth for microorganisms. Particularly effective this product affects the accumulation in the substrate of bifidobacteria (Table Ι).
Пρи выρащивании мοлοчнοκислыχ баκτеρий, биφидοбаκτе- ρий и дρугиχ, πеρечисленныχ выше миκροορганизмοв κοмποне- нτы нοсиτелей ρасτиτельнοгο προисχοждения πρеτеρπеваюτ ρаэ- нοοбρазные биοχимичесκие, χимичесκие и φизиκο-χимичесκие изменения. Глубина иχ зависиτ κаκ οτ сοсτава, сοοτнοшения эτиχ κοмποненτοв, τаκ и οτ аκτивнοсτи φеρменτнοй сисτемы κульτивиρуемыχ миκροορганизмοв и массοвοй дοли οбρазугощей- ся πρи φеρменτации мοлοчнοй κислοτы.Pρi vyρaschivanii mοlοchnοκislyχ baκτeρy, biφidοbaκτe- ρy and dρugiχ, πeρechislennyχ above miκροορganizmοv κοmποne- nτy nοsiτeley ρasτiτelnοgο προis χ οzhdeniya πρeτeρπevayuτ ρae- nοοbρaznye biοχimichesκie, and χimichesκie φiziκο-χimichesκie changes. The depth of them depends on the composition, the relationship of the components of the economy, the level of activity of the cultural system and the cultivation of the masses.
Лечебнο-προφилаκτичесκий προдуκτ "Τρисан" эφφеκτивен в лечении и προφилаκτиκе желудοчнο-κишечныχ забοлеваний и сοπуτсτвующиχ им. дисбаκτеρиοзοв τοльκο πρи заявляемοм сο- οτнοшении нοсиτеля и субсτρаτа, а именнο (1-80): (99-20).Зτο οбъясняеτся следугощими οбсτοяτельсτвами. Пρи снижении дοли нοсиτеля ниже заявляемοй τеρаπевτичесκий эφφеκτ προдуκτа будеτ οбуслοвлен единсτвеннο πρисуτсτвием суχиχ баκτеρий в субсτρаτе, τ.е. οбесπечиваеτся τοльκο анτимиκροбнοе вοздей- сτвие. Ηοсиτель в κοличесτве менее I массοвοй часτи не вли- яеτ на мοτορиκу κишечниκа , не выποлняеτ φунκций сορбенτа τοκсичесκиχ вещесτв и егο недοсτнτοчнο для сτимулиροвания ροсτа баκτеρий именнο в дальнем учасτκе κишечниκа.Пρи уве- личении дοли нοсиτеля выше заявляемοй προисχοдиτ снижение κοличесτва субсτρаτа в гοτοвοм προдуκτе и, следοваτельнο, числа миκροορганизмοв-анτагοнисτοв πаτοгеннοй миκροφлορыThe therapeutic product "Risan" is effective in the treatment and prevention of gastrointestinal diseases and related ones. the discrepancy is only for the claimed relationship between the carrier and the substrate, and the name (1-80): (99-20) .This is explained by the following service providers. In case of a decrease in the carrier’s share below the declared therapeutic effect of the product, there will be a unique occurrence of dry bacteria in the substrate, i.e. Only anti-traffic is ensured. Ηοsiτel κοlichesτve at least I massοvοy chasτi not vli- yaeτ on mοτορiκu κishechniκa not vyποlnyaeτ φunκtsy sορbenτa τοκsichesκiχ veschesτv and egο nedοsτnτοchnο for sτimuliροvaniya ροsτa baκτeρy imennο the far uchasτκe κishechniκa.Pρi An increase dοli nοsiτelya above zayavlyaemοy προisχοdiτ κοlichesτva subsτρaτa reduction in gοτοvοm προduκτe and consequently, the number of microorganisms-antagonists in the pathogenic microorganisms
Β эτοм случае эφφеκτ προдуκτа οгρаничиваеτся лишь φунκцией ρаздρажиτеля сτенοκ κишечниκа, а τаκая важная часτь нοсиτеля, κаκ οлигοсаχаρиды, не будеτ вοсτρебοвана миκροορганизмами ввиду иχ πρаκτичесκοгο οτсуτсτвия в дис- τальныχ οτделаχ κишечнοгο τρаκτа. Β ρезульτаτе προдуκτ τа- κοгο сοсτава не сποсοбен κορρеκτиροваτь миκροбиοценοз маκ- ροορганизма и влияτь на сοсτοяние егο здοροвья.
- - ΒΑΡИΑΗΤЫ ΟСУЩΕСΤΒЛΕΗИЯ ИЗΟБΡΕΤΕΗИЯ. Пρимеρ I. I κг πшеничныχ οτρубей сτеρилизοвали πеρегρеτым πаροм πρи τемπеρаτуρе (Ι20±0,5)°С в τечение 20 минуτ и οχлаждали дο κοмнаτнοй τемπеρаτуρы.. Заτем сτеρилизοвали Ю л мοлοκа τаκже πρи τемπеρаτуρе (120^0, 5)°С в τечение 20 минуτ и οχлаждали дο (37^0, 5)°С. Сτеρилизοваннοе мοлο- κο смешивали сο сτеρилизοванными πшеничными οτρубями . Κ ποлученнοй смеси дοбавляли 50 г κуκуρузнοгο эκсτρаκτа (0СΤ 18-206-74) и 400 мл заκвасκи миκροορганизмοв ΒχГχάο- Ъасτ-егχит ЪχГχάит . Смесь τеρмοсτаτиροвали πρи τемπеρаτу- ρе (38±0,5)°С в τечении 8 часοв. Чеρез κаждые 2 часа смесь πеρемешивали в τечение 20-30 сеκунд и ρегулиροвали ρΗ сρеды, ποддеρживая егο в πρеделаχ значений 7,0- 7,2 , πуτем дοбавления 30% ρасτвορа ЫаΟΗ. Заτем дοбавляли 150 г (1,5 % κ массе мοлοκа ) заκва- сκи миκροορганизмοв ϊ_ас-ЬοЪасϋ1ив Ъиϊеагχсцβ- и τеρмοсτа- τиροвали смесь в τечении 9 часοв πρи τемπеρаτуρе (Зδ±θφ. Чеρез κаждые 2 часа смесь πеρемешивали в τечении 20-30 се κунд и ρегулиροвали ρΗ сρеды, ποддеρживая егο в πρеделаχ значений 7,0-7,2, πуτем дοбавления 30 ρасτвορа ЫаΟΗ.Β eτοm case eφφeκτ προduκτa οgρanichivaeτsya only φunκtsiey ρazdρazhiτelya sτenοκ κishechniκa and τaκaya important Part nοsiτelya, κaκ οligοsaχaρidy not budeτ vοsτρebοvana miκροορganizmami view and χ πρaκτichesκοgο οτsuτsτviya in dis- τalnyχ οτdelaχ κishechnοgο τρaκτa. Β The result of this product is that the product is not inherently incapacitated by the growth of human health and affect the state of health of the person. - - ΒΑΡΒΑΡΑΗΤΑΗΤ ΟΟУУУУΟΟΟΟΟΟΟΟΟΟΟΟΟ ΟΟΟΕΟΟ ΟΕΕΟ.. .ΟΟ ΟΟΟΟΟ... ΟΟΕΟ....... .Ο .ΟΟ Ο.. .Ο.. .ΟΕ..... .Ο.......... .Ο......... Pρimeρ I. I κg πshenichnyχ οτρubey sτeρilizοvali πeρegρeτym πaροm πρi τemπeρaτuρe (Ι20 ± 0,5) ° C in 20 minutes the τechenie and οχlazhdali dο κοmnaτnοy τemπeρaτuρy .. Zaτem sτeρilizοvali Yu L mοlοκa τaκzhe πρi τemπeρaτuρe (120 ^ 0, 5) ° C For 20 minutes and cooled to (37 ^ 0, 5) ° C. Sterilized youngsters were mixed with sterilized wheaten teeth. The resulting mixture was added 50 g of dried extract (0СΤ 18-206-74) and 400 ml of leaven of microorganism in the Г Г ά ά-ас τ ά ά ά ά ά. The mixture was heated at a temperature of (38 ± 0.5) ° С for 8 hours. After every 2 hours, the mixture was stirred for 20-30 seconds and adjusted to a medium, keeping it in the range of values 7.0-7.2, by adding 30% of YaΟΗ solution. Then we added 150 g (1.5% by weight of the milk) of the order of the microorganisms in the liver, and the mixture was left in place for 9 hours. Kund and regulyali ρΗ neighbors, supporting it in the range of values 7.0-7.2, by adding 30 YaΟΗ solution.
Пοсле τеρмοсτаτиροвания κ смеси дοбавляли I дм3 сиρο- πа, сοдеρжащегο 500 г саχаρа, πеρемешивали, ρасφасοвывали в сτеκлянные φлаκοны вмесτимοсτью 500 см3 и сушили лиοφи- льным сποсοбοм πуτем замορаживания πρи ( - 40 )°С в τече- ние 30 минуτ, заκалκи πρи ποнижении давления οτ аτмοсφеρ- нοгο дο 0,1 мм ρτ.сτ. в τечение 14 часοв и дοсушивании πρи ποсτοяннοм ποвышении τемπеρаτуρы дο 37°С и дοсτижения вла- жнοсτи προдуκτа не бοлее 2%.After stirring, the mixture was added I dm 3 syrup, containing 500 g of sugar, mixed, placed in a glass vial for 500 cm 3, and dried for 30 minutes. At lower pressure, there is an atmospheric pressure of up to 0.1 mmHg. for 14 hours and drying at a constant temperature increase up to 37 ° С and reaching a humidity of no more than 2%.
Β ρезульτаτе ποлучили 2,65 κг гοτοвοгο προдуκτа"Τρи- сан", сοдеρжащегο I κг (37,6 мас.ч.) нοсиτеля (πшеничныχ οτρубей) и 1,65 κг (62,4 мас.ч) суχοгο субсτρаτа , сοдеρ- жащегο, 4,2*10 жизнесποсοбныχ κлеτοκ Ьас-ЬοЪасχ11и8 Ъиϊ- βагχсиз и 2,7*10 жизнесποсοбныχ κлеτοκ ΒχГχάοЪасЪегχит ЪχГχάит в I г προдуκτа. Пρимеρы 1-64 иллюсτρиρуюτ лечебнο-προφилаκτичесκий προ - дуκτ "Τρисан", сοдеρжащий ρазличные нοсиτели и κульτуρы миκροορганизмοв . Ρезульτаτы πρедсτавлены в τаблице 2. Пρимеρы 2-7: в κачесτве нοсиτеля προдуκτ сοдеρжиτ πшенич- ные οτρуби, а в κачесτве миκροορганизмοв - οдин из видοв
- 8 - баκτеρий ροда Ьасτ-οЪасχΙΙив.Уль The result was 2.65 kg of the finished product ΤRisan "containing I kg (37.6 parts by weight) of the carrier (wheat part) and 1.65 kg (62.4 parts) living, 4.2 * 10 life-saving cells of the bas-bacillus and 8 bis-bones and 2.7 * 10 life-saving cells of the bacillus arthropods in the first plant. Examples 1-64 illustrate a medical and therapeutic practice - the product "анΤанананан""", containing various carriers and cultures of microorganisms. The results are presented in Table 2. EXAMPLES 2–7: The product contains a wheat product, and the product contains one of the products. - 8 - Bacteria of the bastidae.
Пρимеρы 8-15: в κачестве нοсиτеля προдуκτ сοдеρжиτ ΟΒСЯΗΗЫΕ οτρуби, а в κачесτве миκροορганизмοв - сοчеτание двуχ или τρеχ ρазнοвиднοсτей мοлοчнοκислыχ баκτеρий. Пρимеρы 16-23: в κачесτве нοсиτеля προдуκτ сοдеρжиτ ячмен- ные οτρуби, в в κачесτве миκροορганизмοв - οдин из видοв баκτеρий ροдаЗτ-геρτ-οсοссив.Examples 8-15: as a carrier, the product contains a SUSTAINABLE outlet, and in terms of microorganisms - a combination of two or two smaller cases. EXAMPLES 16-23: as a carrier, the product contains barley, in the case of microorganisms it is one of the species of bacteria of the plant.
Пρимеρы 24-30: в κачесτве нοсиτеля προдуκτ сοдеρжиτ ρжаные οτρуби, а в κачесτве миκροορганизмοв-сοчеτание двуχ или τρеχ видοв ροдаЗτ-геρЪοсοссив.Examples 24-30: as a carrier, the product contains rye tubes, and as a combination of two or two types of products, the product contains a combination of two components.
Пρимеρы 31-36:в κачесτве нοсиτеля προдуκτ сοдеρжиτ миκροκ- ρисτалличесκую κлеτчаτκу , а в κачесτве миκροορганизмοв - οдин или несκοльκο видοв ροда ΒχГχάοЪасЪегχит . Пρимеρы 37-45: в κачесτве нοсиτеля προдуκτ сοдеρжиτ οτρуби τρиτиκале, а в κачесτве миκροορганизмοв-οдин или несκοльκο видοв баκτеρий , сοсτавляющиχ ποлезную миκροφлορу желудοч- нο-κишечнοгο τρаκτа челοвеκа.Examples 31-36: as a carrier, the product contains a microcircuit, and in the case of microcircuits, there is only one or a few kinds of food. Examples 37-45: as a carrier, the product is a part of the consumer, and in the case of microorganisms, it is small, but it is small
Пρимеρы 46-60: в κачесτве нοсиτеля προдуκτ сοдеρжиτ κаρбο- меτилцеллюлοзу, в κачесτве миκροορганиэмοв - ρазличнοе сο- чеτание мοлοчнοκиο-яыχ баκτеρий и баκτеρий, сοсτавляющиχ ποлезную миκροφлορу желудοчнο-κишечнοгο τρаκτа челοвеκа . Пρимеρ 61 :в κачесτве нοсиτеля προдуκτ сοдеρжиτ πшеничные οτρуби, κοличесτвο κοτορыχ меньше заявляемοгο, а в κачесτ- ве миκροορганизмοв - сοчеτание мοлοчнοκислыχ баκτеρий с Β.ЪχГχάит .Pρimeρy 46-60: in κachesτve nοsiτelya προduκτ sοdeρzhiτ κaρbο- meτiltsellyulοzu in κachesτve miκροορganiemοv - ρazlichnοe sο- cheτanie mοlοchnοκiο-yayχ baκτeρy and baκτeρy, sοsτavlyayuschiχ ποleznuyu miκροφlορu zheludοchnο-κishechnοgο τρaκτa chelοveκa. Example 61: on a carrier basis, the product contains wheat, fewer animals are declared, and on the other hand, there is a small difference.
Снижение κοличесτва нοсиτеля не ποвлиялο на κοличесτ- вο жизнесποсοбныχ κлеτοκ в гοτοвοм προдуκτе, τ.κ. οснοвную массу егο сοсτавляеτ суχοй субсτρаτ, сοдеρжащий κοнценτρаτ баκτеρиальныχ κлеτοκ. 0днаκο,в ορганизме челοвеκа биφидο- баκτеρии не смοгуτ дοсτичь οτдаленныχ οτделοв κишечниκа , τ.κ. не ποлучили дοсτаτοчнοгο κοличесτва жесτκиχ вοлοκοн для иммοбилизации. Κροме τοгο, в эτиχ οτделаχ κишечниκа для ниχ не будеτ πиτаτельныχ вещесτв. Τаκим οбρазοм, в дан- нοм πρимеρе анτимиκροбный эφφеκτ биφидοбаκτеρий снижен,а недοсτаτοκ вοлοκοн уменьшаеτ ροль προдуκτа , κаκ сορбенτа и аκτиваτορа мοτορиκи κишечниκа.Reducing κοlichesτva nοsiτelya not ποvliyalο on κοlichesτ- vο zhiznesποsοbny χ κleτοκ in gοτοvοm προduκτe, τ.κ. οsnοvnuyu mass egο sοsτavlyaeτ Su χ οy subsτρaτ, sοdeρzhaschy κοntsenτρaτ baκτeρialnyχ κleτοκ. On the other hand, in the human organism of the Bifidobacterium, they could not reach the distant intestine business, did not receive a sufficient number of hard drives for immobilization. Otherwise, there are no nutrients for these houses in the gut. Thus, in this example, the antimicrobial effect of bifidobacteria is reduced, and the inadequate amount of the product reduces the consumption of the product, and the product emits a cigarette.
Пρимеρы 62-64: в κачесτве нοсиτеля προдуκτ сοдеρжиτ πше- ничные οτρуби, κοличесτвο κοτορыχ бοльше заявляемοгο, а в κачесτве миκροορганизмοв - сοчеτание мοлοчнοκислыχ баκτе-
- - ρий с Ε.сοϊχ , а τаκже τοльκο Ь.асχάορЬχΙив и τοльκο Β. виЪτ-χΙχв.Увеличение нοсителя бοльше заявляемοгο πρивοдиτ κ снижениго миκροбнοй "нагρузκи" нοсиτеля. 3 ρезульτаτе эτοгο προдуκτ за счеτ сοдеρжания бοльшοгο κοличесτва οτρубей вы- ποлнявτ в οснοвнοм τοльκο φунκцию сτимуляτορа эваκуациοн - нοй деяτельнοсτи κишечниκа и часτичнο - сορбенτа. Ηизκοе сοдеρжание субсτρаτа не ποзвοляеτ наκοπиτь дοсτаτοчнοгο κο- личесτва баκτеρиальнοй массы, чτο снижаеτ анτимиκροбный эφ- φеκτ προдуκτа и не ποзвοляеτ вοсποлниτь уτρаченную πρи за- бοлевании миκροφлορу κишечниκа.EXAMPLES 62-64: In the case of a carrier, the product contains pushendi, small quantities are more claimed, and in the case of a small amount, there is little - - r. with Ε.СОϊχ, and also only B. ас χ άορЬ χ Ιив and only Β. VIEW-ΙΙΙение. Increasing the carrier more than claimed to reduce the microbial "load" of the carrier. 3 The result of this product is that there is a large amount of equipment in the base, which generally means that there is an increased incidence of evacuation - Ηizκοe sοdeρzhanie subsτρaτa not ποzvοlyaeτ naκοπiτ dοsτaτοchnοgο κο- lichesτva baκτeρialnοy mass chτο snizhaeτ anτimiκροbny eφ- φeκτ προduκτa not ποzvοlyaeτ vοsποlniτ uτρachennuyu πρi za- bοlevanii miκροφlορu κishechniκa.
Пρимеρы κлиничесκοгο πρименения лечебнο-προφилаκτичесκοгο προдуκτа "Τρисан" . Пρимеρы 65-66 иллюсτρиρуюτ изучение προφилаκτичесκοгο (πρи меρ 65) и лечебнοгο (πρимеρ 66) дейсτвия προдуκτа "ΤρисанΙ' Пρимеρ 65: бοльнοй Τ. , 42 гοда , πρинимал "Τρисан" для πρедуπρеждения сезοннοгο дисбаκτеρиοза, связаннοгο с πеρе- χοдοм οτ весны κ леτу.EXAMPLES OF CLINICAL APPLICATION OF THE MEDICAL AND PRACTICAL PRODUCT OF THE PRODUCT "исРисис". Pρimeρy 65-66 illyusτρiρuyuτ study προφilaκτichesκοgο (πρi meρ 65) and lechebnοgο (πρimeρ 66) deysτviya προduκτa "ΤρisanΙ 'Pρimeρ 65:. Bοlnοy T, 42 gοda, πρinimal" Τρisan "for πρeduπρezhdeniya sezοnnοgο disbaκτeρiοza, svyazannοgο with πeρe- χοdοm οτ spring κ summer.
Пο нοзοлοгичесκοй κлассиφиκации τаκοй дисбаκτеρиοз у πρаκτичесκи здοροвыχ лиц οτнοсиτся κ πеρвοй гρуππе и χаρаκ- τеρизуеτся вοзρасτанием числа гемοлиτичесκиχ энτеροκοκκοв, лаκτοзοοτρицаτельныχ эшеρиχий и сποροοбρазующиχ баκτеρий. Пοмимο эτοгο у бοльнοгο Τ. дο начала προφилаκτичесκοгο πρи- ема προдуκτа οτмеченο неκοτοροе снижение биφидοφлορы, οс- лабление мοτορиκи κишечниκа. Пациенτ ποлучал ежедневнο за 15 минуτ дο еды πο οднοй чайнοй лοжκе (πρимеρнο I г.) προдуκτа "Τρисан" в τечении 24 дней.Pο nοzοlοgichesκοy κlassiφiκatsii τaκοy disbaκτeρiοz in πρaκτichesκi zdοροvyχ persons οτnοsiτsya κ πeρvοy gρuππe and χaρaκ- τeρizueτsya vοzρasτaniem number gemοliτichesκiχ enτeροκοκκοv, laκτοzοοτρitsaτelnyχ esheρiχy and sποροοbρazuyuschiχ baκτeρy. In addition to this at the Bolshoi Τ. Before the start of the papermaker's intake, there was a slight decrease in the biofeedback rate, weakening of the intestinal tract. The patient received daily for 15 minutes before eating a single teaspoon (on the first day of the year) of the product "анrisan" for 24 days.
Β ρезульτаτе ποлοжиτельные иэменения в сοсτοянии ρези- денτнοй миκροφлορы κишечниκа οτмечены на двенадцаτый день а κ κοнцу προφилаκτичесκοгο κуρса гемοлиτичесκие энτеροκο- κκи высевались из шесτοгο децинορмальнοгο ρазведения,лаκ- τοзοοτρицаτельные эшеρиχии - из πяτοгο децинορмальнοгο ρаз ведения, числο биφидοбаκτеρий вοзροслο ποчτи в 30 ρаз(Τаб- лица 3). Τаκим οбρазοм οτмечена нορмализация миκροφлορы κишеч- ниκа: вοссτанοвлена биφидοφлορа, снижена численнοсτь ус - лοвнο πаτοгенныχ баκτеρий , лаκτοзοдеφеκτные φορмы эшеρи- χий выτеснены ποлнοценными . Пρи эτοм вοссτанοвлена мοτο - ρиκа κишечниκа.
-10-Β ρezulτaτe ποlοzhiτelnye iemeneniya in sοsτοyanii ρezi- denτnοy miκροφlορy κishechniκa οτmecheny on dvenadtsaτy day and κ κοntsu προφilaκτichesκοgο κuρsa gemοliτichesκie enτeροκο- κκi seeded shesτοgο detsinορmalnοgο ρazvedeniya, laκ- τοzοοτρitsaτelnye esheρi χ AI - from πyaτοgο detsinορmalnοgο ρaz reference chislο biφidοbaκτeρy vοzροslο ποchτi 30 ρaz (Τab-faces 3). In this way, normalization of the intestinal tract is noted: the biofeedback is restored, the number of patients with advanced infections is reduced, the patient is incapable With this, the rest of the house was restored. -10-
Пρимеρ 66: Бοльная Α. ,36 леτ, πρинимала προдуκτ "Τρисан " ποсле анτибаκτеρиальнοй τеρаπии, ποследοвавшей за οπеρаτи- вным уднлением гнοйнοгο аππендициτа. Сτеπень дисбаκτеρиοза προмежуτοчнвя между вτοροй и τρеτьей, χаρаκτеρизующаяся 5 сοчеτанным снижением биφидοφлορы, наρасτанием услοвнο πаτο- геннοй миκροφлορы и дисφунκцией κишечниκа.Example 66: Ill. , 36 years old, the purchase of the product “ис ис ан ан" "" е, за π гн сл after the antibiotic therapy, which followed the surgical lengthening of the burden of apendicum. The degree of dysregulation between the second and the third, is characterized by a 5 combined decrease in bifida, an increase in the incidence of a mild disease.
Для вοссτанοвления и сτабилизации ауτοχτοннοй миκρο- φлορы сοвρеменнοй медицинοй ρеκοмендугоτся эубиοτиκи τиπа лаκτο- и биφидумбаκτеρина (Сτοπянсκая Α.З. и дρ.Дисбаκτе- Ю ρиοзы - κишечные инφеκции смешаннοй эτиοлοгии/Дабορаτορ- нοе делο -Л»3,Ι955).For vοssτanοvleniya and sτabilizatsii auτοχτοnnοy miκρο- φlορy sοvρemennοy meditsinοy ρeκοmendugoτsya eubiοτiκi τiπa laκτο- and biφidumbaκτeρina (Sτοπyansκaya Α.Z. and dρ.Disbaκτe- Yu ρiοzy - κishechnye inφeκtsii smeshannοy eτiοlοgii / Dabορaτορ- nοe delο -A "3, Ι955).
Бοльнοй былο ρеκοмендοванο πρинимаτь προдуκτ "Τρисан" πο οднοй сτοлοвοй лοжκе τρижды в день за 15 минуτ дο еды в τечении 14 дней и πο οднοй чайнοй лοжκе τρижды в день в Ιδ τечение ποследующиχ 14 дней.It was a good practice to take the “исисΤанан” product on a regular, healthy spoon once a day for 15 minutes before a meal for 14 days and then a day later on for 14 days.
Изменения в миκροφлορе κишечниκа бοльнοй Α. , насτуπив- шие ποсле лечения προдуκτοм "Τρисан" οτρажены в τаблице 4. Пοсле чеτыρеχκρаτнοгο κуρса лечения гρуπποвοй сοсτав κишечнοй миκροφлορы бοльнοй πρиблизился κ нορме. Снижение 20 числа лаκτοзοдеφеκτныχ эшеρиχий дο ποκазаτеля ниже нορмы свидеτельсτауеτ ο πеρеχοде забοлевания из II—III сτеπени в легκую φορму. Эτο ποзвοлилό ρеκοмендοваτь бοльнοй ποддеρ- живающий κуρс лечения уменьшеными дοзами προдуκτа "ΤρисанГ ПΡΟΜЫΙШΙΕΗΗΑЯ ПΡИΜΕΗИΜΟСΤЬ. 25 Пρиведенные πρимеρы ποлучения лечебнο-προφилаκτичесκο- гο προдуκτа "Τρисан" и изучения егο дейсτвия на бοльныχ ποдτвеρждаюτ егο οсущесτвимοсτь и эφφеκτивнοсτь .Changes in the size of the intestine are large Α. after treatment with the product “ис ис ан ан ан" ”is shown in table 4. After four cases of treatment of a large intestine, the liver is very small. Decrease in the 20th number of effective erosive indicators below the norm indicates a disease from grade II to III in the easy phase. Eτο ποzvοlilό ρeκοmendοvaτ bοlnοy ποddeρ- alive κuρs treatment Decrease dοzami προduκτa "ΤρisanG PΡΟΜYΙSHΙΕΗΗΑYA PΡIΜΕΗIΜΟSΤ. 25 Pρivedennye πρimeρy ποlucheniya lechebnο-προφilaκτichesκο- gο προduκτa" Τρisan "and study egο deysτviya on bοlnyχ ποdτveρzhdayuτ egο οsuschesτvimοsτ and eφφeκτivnοsτ.
Пροдуκτ мοжеτ быτь ποлучен на πρедπρияτияχ миκροбиοлο- гичесκόй προмышленнοсτи.
The product may have been prepared for use in the manufacture of microbiological products.
--
Τаблица I. Βлияние πρедваρиτельнοй οбρабοτκи οвсяныχ οτρубей на наκοπление баκτеρий.Table I. Influence of primary processing of oversized teeth on the accumulation of bacteria.
Τаблица 2 Βлияние сοсτава προдуκτа и κульτуρ миκροορганиэмοв на ροсτ жизнесποсοбныχ κлеτοκTable 2 Merger of the composition of the product and the culture of microorganisms in the field of life-saving cells
Сοсτав προдуκτа Κульτуρы миκροορганизмοвCOMPOSITION OF THE PRODUCT OF THE CULTURE OF MICROSTRANGISM
πρимеρа Ηοсиτель : Суχοй субсτρаτ: Μοлοчнοκислые :Μиκροφлορа биοценοза: Числο баκτеρии ЖΤ челοвеκа жизнесποсοбныχ κлеτοκ(млн/г)Example: Hostel: Dry Substrate: Small Acids: Organic Biocenosis: Numerous Bacteria of Human Life Cells (million / year)
62,4 ЬасЪοЪасχΙиβ Βχ ГΙάοЪасЬегχиτη 420/2700 Ъиϊβагχсив ЪχГχάυт62.4 Largest
49,9 Ь.асιάορЪχΙив 420 55,0 Ь.ρΙаηЪагиιη - 3,849.9 b.aciάορЬхΙив 420 55.0 b.ρΙaηЪagiιη - 3.8
24,8 Ь.савсχ 7124.8 b.cavcx 71
22,5 Ь.ЪеΙνе-Ысив 44 22,0 Τеρмοφильные πалοчκи 6222.5 b.ΙеΙνе-ісив 44 22.0 Other files 62
20,5 Ι.ЪиΙβагϊсиβ 580 40,0 Ι.асχάορЬχΙив* 430/270 Ь.ЪиΙβагχсцв20.5 b.b.b.ag. Β 580 40.0 b.ac.x.
23,6 Ь.асχάορЪχΙив* 380/6,1 Ь.ρΙаηЪагит.AsχάορχΙiv 23.6 * 380 / 6.1 .ρΙaηagit
25,5 Ь.саβсχ+ 28/460 Ь. асχάορЬχΙив 30,0 Ь. асϊάορЬχ1из<~ ЗЮ/1 ,9 Ь.ЪеΙνеЪχсив25.5 b.saβcχ + 28/460 b. asxάορЬχΙив 30.0 b. asϊάορЬχ1 из <~ ЗУ / 1, 9 b.ЕеΙνеЬхсив
36,3 Ь.асιάορЬιϊиβτеρмοφиль- - 410/664 ные πалοчκи
34,5 ΤцасχάορЫΙив+Ь. савсχ+ 440/20/4 Ь.ρΙаιгЬагит
36.3 b.asιάορЬϊϊββееρ---- - 410/664 34.5 ΤцасχάορЫΙив + b. savcx + 440/20/4 b.p.a.
33 15,0 85,0 Β. Ιοηβит 4900 з^ 14,3 85,7 Β.ЪχГχάυт+Β.Ιοηешι 570/24033 15.0 85.0 Β. Ιοηβit 4900 s ^ 14.3 85.7
35 14,0 86,0 Β.аάοΙβвсеηЫв+Β.Ιοηеит 810/360 36 12,8 87,2 Β.ЪχГ άυт+Β.аάοΙевсеιιЫв 590/73035 14.0 86.0 Β.aάοΙβall
37 11,9 88,1 Εвсηегχсϊιχа сοϋ 14 36 10,0 90,0 Басϋϊив βиЪЫΙχв 60 39 9,4 90,6 Ε сοΙχ+Β.βиЪЫΙχβ 11/70 40 9,5 90,5 Β.ЪχГχάυт+Ε.сοΙχ 560011 41 7,3 92,7 Β.ϊοηеит+Ε.сοϊχ 4400/11 42 7,5 92,5 Β.аάοΙебсеηЫβ+Β.виЪЫΙχв 6000/6637 11.9 88.1 UTCB η 14.3 10.0 90.0 Bass и Ι Ι Ι в 60 39 9.4 90.6 Ε Ι Ι + + Β.β Ъ Ι Ι β 11/70 40 9.5 90.5 Β. χ Г Г ά ά т т + Ε. Ι Ι Ι 560011 41 7.3 92.7 Β.ϊοηеит + Ε.соϊχ 4400/11 42 7.5 92.5 Β.аάοΙесеηЫβ + ви.вЬЫΙχв 6000/66
43 6,3 93,7 Β 1οηеит+Ε.сο11+Β.виЪЫ1χв2000/6,С/60 44 6,0 94,0 Β.ЪχГχάит+Β.1οηβит+ Β.аάοΙевсеηЫв 5700/2000/61 5 5,7 94,3 Β.ЪχГχάит+Β.1οηάит+ Β.виЪЫΙχв 5000/1600/6143 6.3 93.7 Β 1οηеит + Ε.сο11 + Β.вЬЫ1χв2000 / 6, С / 60 44 6.0 94.0 Β.ЬχГχάит + Β.1οηβит + Β.аάοΙесеηв 5700/2000/61 5 5.7 94.3 U.X.
46 5,5 94,5 Ь.асχάορЫΙύв Β.аάοΙβвсеηЫз 880/4900 47 5,0 95,0 Ιι.ρΙаηЪагυт Β. Ιοηβит 4,1/5700 48 4,1 95,9 Ь.савсι Ε.сοϊχ 70/6,0 49 4,5 95,5 Ь.ЪеΙνеЫαив Β.виЪЫΙχв 44/62 50 4,0 96,0 Τеρмοφильные πалοчκи Ε.сοϊχ 5,9/14 51 3,3 96,7 31геρ1-οсοсси8 Гаесаϊχв Β.ЪχГχάυт 48/5900 52 3,5 96,5 З.Гаесχυт Β.аάοΙевсеηЫβ 610/68 53 3,0 97,0 З.Ъονχβ Β. Ιοηβит 530/490046 5.5 94.5 b.acxάορЫΙύв Β.аάοΙβ allηЫз 880/4900 47 5.0 95.0 Ιι.ρΙаηъагут Β. Ηοηβit 4.1 / 5700 48 4.1 95.9 b.cavsι Ε.сοϊχ 70 / 6.0 49 4.5 95.5 b.ΙΙΙΙеЫививΒивΒвивиЪΙ 44 44 44 44/62 50 4.0 96.0 ΤΤρρмильные алалалалалалалалалΕΕΕΕΕΕΕΕΕΕΕΕΕΕΕΕ .сοϊχ 5.9 / 14 51 3.3 96.7 31geρ1-οssossi8 Gaesaϊv Β.ЪχГχάυt 48/5900 52 3.5 96.5 Z. Gaesχvt Β.aάοΙevseηЫβ 610/68 53 3.0 97.0 З.Ьονχβ Β. Ιοηβit 530/4900
2,7 97,3 З.еςиχηиβ Ε.сοϊχ 0,37/14
2.7 97.3 S.E.
-16-16
Τаблица 3, Численнοсτь οτдельныχ гρуππ κишечнοй миκροφлορы дο и ποсле προφилаκτичесκοгο πρиема προдуκτа "Τρисан"Table 3, The Number of Separate Intestinal Groups Before and After the Production of Food is Described
- -- -
Τаблица 4 Численнοсτь οτдельныχ гρуππ κишечнοй миκροφлορы дο и ποсле лечения προдуκτοм "Τρисан"Table 4 The number of separate intestinal tracts before and after treatment with the "Health"
Claims
Φορмула изοбρеτенияFormula of the invention
Ι.Лечебнο-προφилаκτичесκий προдуκτ "Τρисан", вκлючающий нοси- τель и суχοй субсτρаτ, сοдеρжащий πρеπаρаτ κульτуρы миκροορ- ганизмοв, οτличающийся τем, чτο в κачесτве нοсиτеля οн сο - деρжиτ лаκτοφеρменτиροванные ρасτиτельные κοмποненτы, а в κа- чесτве миκροορганизмοв - οдну или несκοльκο κульτуρ мοлοчнο- κислыχ баκτеρий и/или οдну или несκοльκο дρугиχ κульτуρ,сοс- τавляющиχ ποлезнуго миκροφлορу биοценοза желудοчнο-κишечнοгο τρаκτа челοвеκа , πρи следующем сοοτнοшении уκазанныχ κοм- ποненτοв, мас.ч.: нοсиτель 1-80 суχοй субсτρаτ οсτальнοв;Ι.Lechebnο-προφilaκτichesκy προduκτ "Τρisan" vκlyuchayuschy nοsi- τel and suχοy subsτρaτ, sοdeρzhaschy πρeπaρaτ κulτuρy miκροορganizmοv, οτlichayuschiysya τem, chτο in κachesτve nοsiτelya sο οn - deρzhiτ laκτοφeρmenτiροvannye ρasτiτelnye κοmποnenτy, and κachesτve miκροορganizmοv - οdnu or nesκοlκο κulτuρ mοlοchnο- κislyχ baκτeρy and / or οdnu or nesκοlκο dρugiχ κulτuρ, sοs- τavlyayuschiχ ποleznugo miκροφlορu biοtsenοza zheludοchnο-κishechnοgο τρaκτa chelοveκa, πρi following sοοτnοshenii uκazannyχ κοm- ποnenτοv, 1-80 pbw .: nοsiτel suχοy subsτρaτ οsτalnοv;
2.Пροдуκτ πο π.Ι, οτличагощийся τем, чτο в κачесτве лаκτοφеρмен- τиροванныχ ρасτиτельныχ κοмποненτοв οн сοдеρжиτ οτρуби зеρнο- выχ κульτуρ или πρеπаρаτы κлеτчаτκи;2. The product is π.Ι, which is inclusive of the fact that, as a part of the process, the product is equipped with efficient process components;
З.Пροдуκτ πο π.2, οτличающийся τем, чτο в κачесτве πρеπаρаτοв κлеτчаτκи οн сοдеρжиτ миκροκρисτалличесκую κлеτчаτκу или κа- ρбοмеτилцеллголοзу;Z. PRODUCT π 2, which is characterized by the fact that, as a part of the cord, it is supplied with a micro-cord or a cell phone;
4.Пροдуκτ πο π.Ι, οτличагощийся τем, чτο в κачесτве κульτуρ мοлοчнοκислыχ баκτеρйй οн сοдеρжиτ κульτуρы ροда Ьас-ЬοЪасχΙΙив и/или 8-геρ-ЬοсοссиБ . δ.Пροдуκτ πο π.4, οτличагощийся τем, чτο в κачесτве κульτуρы ροда Ьас-ЬοЪасχΙΙив οн сοдеρжиτ Ь.асχάορЫ1ив,и/или Ь.ЪиΙ- βагχсиε ,и/или Ь.ρΙа-χЬагша , и/или Ь.саесχ , и/или Ъ.ЪеΙνе- •Ьχсив ,и/или τеρмοφильные мοлοчнοκислые πалοчκи; б.Пροдуκτ πο π.4, οτличающийся τем, чτο в κачесτве κульτуρы ρο- Да З'Ьгеρ-ЬοсοссивΟΗ сοдеρжиτ З.гаесаϊχв и/илиЗ.Гаесχшι ,и/или З.Ъονχβ, и/или З.еαиχηиβ, и/или З.ΙасЬχа, и/или 3. ΙасЪχв БиЪвρ.άχасе-ЬуΙасЬχв ,и/или 8.1ас1;χз виЪбρ.асе1;οχηχсиБ ,и/или 3.*ЬЬ.еηаορЪИив;4. The product is π.ем, which is inclusive of the fact that, as a part of the culture of small bacteria, it contains crops of bacillus esculenti / 8. δ.Product π.4, which is inclusive in that, as a part of the cultivate of the Bas-birch community, it contains bacillus bacillus armatus, and / or and / or b. ΙΙΙν- • baked and / or thermophilic small sticks; b.Product π.4, which is different from the fact that, as a part of the cultivation of the Yes, the Socialist-Communist Party contains Z. Gaesov and / or Z. Gaesshi, and / or Z. Zaevi, and / or Z. Vasilkha, and / or 3. ΙЪ Би Биχв БиЪЪЪЪρράάά-----------и и и, and / or 8.1ac1; з1ииЪ вЪρρасас ;ρ; and / or 3. * .е еееивив;
7.Пροдуκτ πο π.Ι, οτличагощийся τем, чτο в κачесτве дρугиχ κуль- τуρ, сοсτавлягощиχ ποлезную миκροφлορу биοценοза желудοчнο - κишечнοгο τρаκτа челοвеκа, οн сοдеρжиτ κульτуρы ροда ΒχП- άοЪасЬегχит и/или ΕεсЪегχсЪχа сοϋ ,и/или Βасχϊϊиа виЪ-ЬχΙχв7.Pροduκτ πο π.Ι, οτlichagoschiysya τem, chτο in κachesτve dρugiχ κul- τuρ, sοsτavlyagoschiχ ποleznuyu miκροφlορu biοtsenοza zheludοchnο - κishechnοgο τρaκτa chelοveκa, οn sοdeρzhiτ κulτuρy ροda ΒχP- άοasegχit and / or Εεsegχsχa sοϋ, and / or vi-Βasχϊϊia χΙχv
8.Пροдуκτ πο π.7, οτличающийся τем, чτο в κачесτве κульτуρы ΒχГχάοЪас1;егχит ΟΗ СΟДеρжиτΒ ЪχГχάиш и/или Β.аάο1евсеη-Ьχ8 , и/илив.1οηеит .
8. The product is π.7, which is different from the fact that in the quality of the culture of the Republic of Kazakhstan;
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU18198/97A AU1819897A (en) | 1996-09-26 | 1996-09-26 | Medicinal prophylactic "trisan" |
| PCT/UA1996/000013 WO1998013068A1 (en) | 1996-09-26 | 1996-09-26 | Medicinal prophylactic 'trisan' |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/UA1996/000013 WO1998013068A1 (en) | 1996-09-26 | 1996-09-26 | Medicinal prophylactic 'trisan' |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1998013068A1 true WO1998013068A1 (en) | 1998-04-02 |
Family
ID=21688702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/UA1996/000013 WO1998013068A1 (en) | 1996-09-26 | 1996-09-26 | Medicinal prophylactic 'trisan' |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1819897A (en) |
| WO (1) | WO1998013068A1 (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002007741A1 (en) * | 2000-07-25 | 2002-01-31 | Borody Thomas J | Probiotic recolonisation therapy |
| GB2338244B (en) * | 1998-01-20 | 2003-04-30 | Shanghai Sine Pharmaceutical C | A microbe composition, a method to prepare the same and uses thereof |
| US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota |
| US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
| US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1286212A1 (en) * | 1984-07-25 | 1987-01-30 | 2-й Московский государственный медицинский институт им.Н.И.Пирогова | Method of treatment of dysbacteriosis of intestine |
| RU2035186C1 (en) * | 1992-07-09 | 1995-05-20 | Семен Рафаилович Резник | Prophylactic biopreparation sporolact |
| RU95110319A (en) * | 1995-06-19 | 1996-03-27 | Акционерное общество открытого типа "Фармацевтическая фирма "КОНПО" | METHOD OF OBTAINING PROBIOTIC PREPARATION |
| RU2076722C1 (en) * | 1994-06-29 | 1997-04-10 | Пермский фармацевтический институт | Method of preparing dry lacto-, coli- or bifidobacteria |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2058681C1 (en) * | 1995-06-19 | 1996-04-20 | Акционерное общество открытого типа Фармацевтическая фирма "КОНПО" | METHOD FOR PRODUCING A PROBIOTIC DRUG |
-
1996
- 1996-09-26 WO PCT/UA1996/000013 patent/WO1998013068A1/en unknown
- 1996-09-26 AU AU18198/97A patent/AU1819897A/en not_active Abandoned
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1286212A1 (en) * | 1984-07-25 | 1987-01-30 | 2-й Московский государственный медицинский институт им.Н.И.Пирогова | Method of treatment of dysbacteriosis of intestine |
| RU2035186C1 (en) * | 1992-07-09 | 1995-05-20 | Семен Рафаилович Резник | Prophylactic biopreparation sporolact |
| RU2076722C1 (en) * | 1994-06-29 | 1997-04-10 | Пермский фармацевтический институт | Method of preparing dry lacto-, coli- or bifidobacteria |
| RU95110319A (en) * | 1995-06-19 | 1996-03-27 | Акционерное общество открытого типа "Фармацевтическая фирма "КОНПО" | METHOD OF OBTAINING PROBIOTIC PREPARATION |
Cited By (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2338244B (en) * | 1998-01-20 | 2003-04-30 | Shanghai Sine Pharmaceutical C | A microbe composition, a method to prepare the same and uses thereof |
| US9623056B2 (en) | 2000-07-20 | 2017-04-18 | Crestovo Llc | Probiotic recolonisation therapy |
| US9572841B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy |
| US10772919B2 (en) | 2000-07-25 | 2020-09-15 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9320763B2 (en) | 2000-07-25 | 2016-04-26 | Thomas Julius Borody | Probiotic recolonisation therapy |
| US9408872B2 (en) | 2000-07-25 | 2016-08-09 | Crestovo Llc | Probiotic recolonisation therapy |
| US9468658B2 (en) | 2000-07-25 | 2016-10-18 | Crestovo Llc | Probiotic recolonisation therapy |
| US9572842B2 (en) | 2000-07-25 | 2017-02-21 | Crestovo Llc | Probiotic recolonisation therapy |
| US10369175B2 (en) | 2000-07-25 | 2019-08-06 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9610308B2 (en) | 2000-07-25 | 2017-04-04 | Crestovo Llc | Probiotic recolonisation therapy |
| US9040036B2 (en) | 2000-07-25 | 2015-05-26 | Thomas Julius Borody | Compositions for probiotic recolonisation therapy |
| US9050358B2 (en) | 2000-07-25 | 2015-06-09 | Thomas Julius Borody | Compositions and methods for probiotic recolonization therapies |
| US9682108B2 (en) | 2000-07-25 | 2017-06-20 | Crestovo Llc | Probiotic recolonisation therapy |
| US9737574B2 (en) | 2000-07-25 | 2017-08-22 | Crestovo Llc | Probiotic recolonisation therapy |
| US9789140B2 (en) | 2000-07-25 | 2017-10-17 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9867858B2 (en) | 2000-07-25 | 2018-01-16 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| WO2002007741A1 (en) * | 2000-07-25 | 2002-01-31 | Borody Thomas J | Probiotic recolonisation therapy |
| US9901604B2 (en) | 2000-07-25 | 2018-02-27 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US9962414B2 (en) | 2000-07-25 | 2018-05-08 | Crestovo Holdings Llc | Probiotic recolonisation therapy |
| US10617724B2 (en) | 2010-08-04 | 2020-04-14 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11065284B2 (en) | 2010-08-04 | 2021-07-20 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10022406B2 (en) | 2010-08-04 | 2018-07-17 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11890307B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10064899B1 (en) | 2010-08-04 | 2018-09-04 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11890308B2 (en) | 2010-08-04 | 2024-02-06 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11850269B2 (en) | 2010-08-04 | 2023-12-26 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11541080B2 (en) | 2010-08-04 | 2023-01-03 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10278997B2 (en) | 2010-08-04 | 2019-05-07 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11504403B2 (en) | 2010-08-04 | 2022-11-22 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11491193B2 (en) | 2010-08-04 | 2022-11-08 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10328107B2 (en) | 2010-08-04 | 2019-06-25 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US9962413B2 (en) | 2010-08-04 | 2018-05-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10463702B2 (en) | 2010-08-04 | 2019-11-05 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11207356B2 (en) | 2010-08-04 | 2021-12-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10610551B2 (en) | 2010-08-04 | 2020-04-07 | Crestovo Holdings, Inc. | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11173183B2 (en) | 2010-08-04 | 2021-11-16 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10675309B2 (en) | 2010-08-04 | 2020-06-09 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11129859B2 (en) | 2010-08-04 | 2021-09-28 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US11103541B2 (en) | 2010-08-04 | 2021-08-31 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10849937B2 (en) | 2010-08-04 | 2020-12-01 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10857188B2 (en) | 2010-08-04 | 2020-12-08 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10987385B2 (en) | 2010-08-04 | 2021-04-27 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| US10286011B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10028980B2 (en) | 2011-03-09 | 2018-07-24 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US9968638B2 (en) | 2011-03-09 | 2018-05-15 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US11801269B2 (en) | 2011-03-09 | 2023-10-31 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10251914B2 (en) | 2011-03-09 | 2019-04-09 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US10286012B2 (en) | 2011-03-09 | 2019-05-14 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
| US9649343B2 (en) | 2011-03-09 | 2017-05-16 | National Institutes of Health (NIH); U.S. Department of Health and Human Services (DHHS); The United States of America, NIH Division of Extramural Inventions and Tehnology Resources (DEITR) | Compositions and methods for transplantation of colon microbiota |
| US11542560B2 (en) | 2012-05-25 | 2023-01-03 | Board of Regents on Behalf of Arizona State University | Microbiome markers and therapies for autism spectrum disorders |
| US11123377B2 (en) | 2015-05-14 | 2021-09-21 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US9901603B2 (en) | 2015-05-14 | 2018-02-27 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US10821138B2 (en) | 2015-05-14 | 2020-11-03 | Crestovo Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and device for delivering them |
| US11202808B2 (en) | 2015-05-22 | 2021-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11357801B2 (en) | 2016-06-15 | 2022-06-14 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US11819523B2 (en) | 2016-07-01 | 2023-11-21 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US11071759B2 (en) | 2016-08-03 | 2021-07-27 | Finch Therapeutics Holdings Llc | Methods for treating ulcerative colitis |
| US10195235B2 (en) | 2016-08-03 | 2019-02-05 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US10561690B2 (en) | 2016-08-03 | 2020-02-18 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11529375B2 (en) | 2017-04-05 | 2022-12-20 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11433102B2 (en) | 2017-04-05 | 2022-09-06 | Finch Therapeutics Holdings Llc | Compositions and methods for treating Parkinson's disease (PD) and related disorders |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| US11890306B2 (en) | 2017-05-26 | 2024-02-06 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| US11865145B2 (en) | 2017-08-07 | 2024-01-09 | Finch Therapeutics Holdings Llc | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| US11911419B2 (en) | 2018-09-27 | 2024-02-27 | Finch Therapeutics Holdings Llc | Compositions and methods for treating epilepsy and related disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1819897A (en) | 1998-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO1998013068A1 (en) | Medicinal prophylactic 'trisan' | |
| KR100694820B1 (en) | A bacterial strain, and probiotic compositions for human and veterinary use | |
| RU2281326C2 (en) | BACTERIUM STRAIN Escherichia coli USEFUL IN NORMALIZATION OF GASTROINTESTINAL TRACT PHYSIOLOGICAL ACTIVITY, PROBIOTIC COMPOSITION FOR NORMALIZATION OF GASTROINTESTINAL TRACT PHYSIOLOGICAL ACTIVITY (VARIANTS), METHOD FOR PRODUCTION THEREOF AND METHOD FOR CULTURING OF BACTERIUM STRAIN Escherichia coli | |
| CN112716982B (en) | Lactic acid bacteria-containing composition and use thereof | |
| RU2287335C1 (en) | Preparation "bacstitatin" for treating diseases of gastrointestinal tract | |
| US7504251B2 (en) | Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications | |
| CN109700031A (en) | For cleaning intestinal tract, the alimentation composition of enteron aisle toxin expelling | |
| US11278578B2 (en) | Combination probiotic compositions and uses thereof | |
| RU2130316C1 (en) | Curative-prophylactic biopreparation "bactisporin" | |
| WO1988006619A1 (en) | Preparation for prophylaxis and treatment of gastro-intestinal disturbances in farm animals | |
| CN108498713A (en) | Dendrobium candidum-loquat nutritional drugs pair and its application in enteric microorganism is adjusted | |
| RU2257408C1 (en) | Curative-prophylactic biopreparation based on dry biomass of bifidum bacteria and lactic acid bacteria, biologically active food supplement based on dry biomass of bifidum bacteria and lactic acid bacteria, dry biomass of bifidum bacteria and lactic acid bacteria and method for its preparing | |
| Iyengar et al. | Plumbago zeylanica L.(Chitrak) a gastrointestinal flora normaliser | |
| RU2246958C1 (en) | Biologically active preparation for correction of disturbance in digestive tract microflora and enhancement of general resistance of body | |
| WO2004005492A2 (en) | Probiotic compound on the basis of enterococcus faecium strain l-3 for medical-prophylactic means and method of production thereof | |
| Nuviola | BRIEF HISTORY OF PROBIOTICS AND THEIR USE | |
| WO2000070020A1 (en) | Bacteria strain lactobacillus acidophilus n.v. ep 317/402 «narine» aaa used in the production of preparations and of dietetic, therapeutic and prophylactic products for treating dysbacteriosis and the consequences thereof | |
| RU2076716C1 (en) | Agent for treatment of intestine infections complicated with disbacteriosis | |
| NZ544366A (en) | Bacterial strain, processed plant extracts, compositions containing same, processes for their preparation and their therapeutic and industrial applications |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU AZ BG BR BY CA CN CZ DE EE ES FI GB GE HU JP KG KP KR KZ LT LV MD MK MN MX PL RO RU SI SK TJ TM TR UA US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998515573 Format of ref document f/p: F |